MASCoD - Multidimensional Assessment of Subjective Cognitive Decline
Launched by ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA · Apr 3, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MASCoD trial is studying a new screening tool designed to help detect and monitor subjective cognitive decline (SCD), which is when people feel like their thinking abilities are getting worse, even if tests don’t show any problems yet. This condition can affect a person’s quality of life and may lead to more serious cognitive issues over time. The goal of the study is to see if the MASCoD tool can accurately identify individuals at risk for severe cognitive decline and track their progress, especially after they undergo cognitive training.
To be eligible for this study, participants need to be over 55 years old, have reported feelings of cognitive decline without any other serious cognitive or neurological issues, and be able to understand the study's aims. They should also be willing to participate voluntarily. Participants will first be evaluated using the MASCoD tool and other cognitive tests, and then they will be placed in either a group that receives cognitive training using technology or a waitlist group. After some time, everyone will be re-evaluated to see how they’ve progressed. This study is currently recruiting participants, and it aims to provide valuable insights into improving cognitive health in older adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • reported subjective cognitive decline without any other cognitive or neurological issue,
- • Italian education,
- • adult (\> 55 years old),
- • understanding of research aims,
- • signed informed consent,
- • participation on a voluntary and non-payied bases.
- Exclusion Criteria:
- • serious clinical conditions (e.g. severe cardiac and respiratory problems, neoplasia)
- • prior diagnosis of psychiatric disorders according to DSM-5,
- • prior diagnosis of cognitive decline,
- • relevant visuo-perceptive or hearing deficits,
- • illiteracy or relapse in illiteracy,
- • refusal to partake in the research.
About Istituti Clinici Scientifici Maugeri Spa
Istituti Clinici Scientifici Maugeri S.p.A. is a prestigious Italian healthcare organization dedicated to advancing medical research and clinical practice. With a strong focus on patient-centered care, the institution integrates innovative clinical trials into its comprehensive services, fostering collaboration between researchers and healthcare professionals. Known for its commitment to high-quality standards and ethical practices, Istituti Clinici Scientifici Maugeri S.p.A. plays a pivotal role in the development of new therapies and treatment modalities, contributing significantly to the global medical community and enhancing patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montescano, Pavia, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials